Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 26, 2015 7:10 PM ET


Company Overview of Sprout Pharmaceuticals, Inc.

Company Overview

Sprout Pharmaceuticals, Inc. develops and offers products for treatment of female sexual health. It offers a non-hormonal pill for the treatment of acquired and generalized hypoactive sexual desire disorder in premenopausal women in the United States. The company was founded in 2011 and is based in Raleigh, North Carolina.

4208 Six Forks Road

Suite 1010

Raleigh, NC 27609

United States

Founded in 2011





Key Executives for Sprout Pharmaceuticals, Inc.

Co-Founder, Chief Executive Officer and Director
Co-Founder and Vice Chairman
Chief Financial Officer
Executive Vice President of Commercial Strategy
Executive Vice President of Corporate and Regulatory Affairs
Compensation as of Fiscal Year 2015.

Sprout Pharmaceuticals, Inc. Key Developments

Sprout Pharmaceuticals, Inc. Announces Addyi

Sprout Pharmaceuticals, Inc. announced that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now available in the United States through certified physicians and pharmacies. Addyi was approved by the U.S. Food and Drug Administration (FDA) on August 18, 2015. The company will offer two avenues of affordable access for women, including the Addyi Affordable Access Card for pharmacies and the AddyiDirect program with doorstep delivery. The approval of Addyi is largely based on three North American, Phase 3, 24-week, randomized double blind, placebo-controlled studies of premenopausal women with HSDD. Addyi was administered to over 2,500 premenopausal women with acquired, generalized HSDD in clinical trials, with over 850 receiving treatment for at least 12 months. For premenopausal women with HSDD, Addyi has demonstrated improvements in desire for sex, reducing distress from the loss of sexual desire and increasing the number of satisfying sexual events. Addyi is not indicated for use in postmenopausal women or men or to enhance sexual function. Addyi was approved with a Boxed Warning. Use of Addyi with alcohol increases the risk of severe hypotension and syncope; therefore, alcohol use is contraindicated. Severe hypotension and syncope occurs when Addyi is used with moderate or strong CYP3A4 inhibitors or in patients with hepatic impairment; therefore use of Addyi in patients with hepatic impairment is also contraindicated. Hypotension, syncope and central nervous system (CNS) depression can occur with Addyi alone. The most common adverse reactions are dizziness, somnolence, nausea, fatigue, insomnia and dry mouth. See full safety information below. Addyi is intended to be administered orally once per day at bedtime with or without food.

Sprout Pharmaceuticals Receives U.S. Food and Drug Administration Approval of Addyi (Flibanserin 100 mg)

Sprout Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted approval of Addyi (flibanserin 100 mg) (pronounced add-ee), a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Addyi is the first and only FDA-approved treatment for this condition, the most common form of female sexual dysfunction, affecting up to 1 in 10 women in the United States. HSDD is defined as a persistent absence of sexual thoughts, fantasies, responsiveness and willingness to engage in sexual activity that causes personal or relationship distress and cannot be accounted for by another medical condition or substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.

Sprout Pharmaceuticals, Inc. - Special Call

To discuss on U.S. Food and Drug Administration approval of Addyi™ (flibanserin 100 mg) (pronounced add-ee)

Similar Private Companies By Industry

Company Name Region
Atrium Biotech Investments, Inc. United States
Plasmogen Inc. United States
Allena Pharmaceuticals, Inc. United States
Beckon Scientific Inc. United States
Ziarco, Inc. United States

Recent Private Companies Transactions

August 20, 2015
Private Placement
May 22, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sprout Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at